Enoxaparin (Clexane) Dosing in Acute Coronary Syndrome
For ACS, use enoxaparin 1 mg/kg subcutaneously every 12 hours as initial therapy, with mandatory dose reduction to 1 mg/kg once daily if creatinine clearance is below 30 mL/min. 1
Standard Dosing Protocol
The 2025 ACC/AHA/ACEP/NAEMSP/SCAI guidelines provide the definitive dosing framework 1:
Initial Medical Management
- Standard dose: 1 mg/kg subcutaneous every 12 hours
- Renal impairment (CrCl <30 mL/min): Reduce to 1 mg/kg subcutaneous once daily (every 24 hours)
For Patients Receiving Fibrinolytic Therapy
Age <75 years:
- 30 mg IV bolus
- Followed in 15 minutes by 1 mg/kg subcutaneous every 12 hours
- Maximum 100 mg for the first 2 doses
Age ≥75 years:
- No bolus (critical pitfall to avoid)
- 0.75 mg/kg subcutaneous every 12 hours
- Maximum 75 mg for the first 2 doses
Regardless of age with CrCl <30 mL/min:
- 1 mg/kg subcutaneous every 24 hours
To Support PCI
If patient already on enoxaparin:
- Last dose 8-12 hours ago OR only 1 dose given: Give 0.3 mg IV
- Last dose within 8 hours: No additional dose needed
If no prior anticoagulation:
- 0.5-0.75 mg/kg IV bolus 1
Critical Dosing Adjustments
Renal Function
The most important adjustment is for renal impairment. Research confirms enoxaparin clearance decreases by 31% in moderate renal impairment and 44% in severe renal impairment, leading to significant accumulation with standard dosing 2. Always calculate creatinine clearance using the Cockcroft-Gault equation before initiating therapy.
Obesity Considerations
While the guidelines specify weight-based dosing without upper limits, emerging evidence suggests potential issues in extreme obesity. Research shows that in patients >150 kg, standard 1 mg/kg dosing may increase bleeding risk 3. However, the 2025 guidelines do not recommend dose capping, and you should follow guideline recommendations of 1 mg/kg dosing 1. If weight exceeds 150 kg, consider anti-Xa monitoring if available, targeting peak levels of 0.5-1.0 IU/mL drawn 4 hours after the third dose.
Common Pitfalls to Avoid
Forgetting the age-based adjustment with fibrinolytics: Patients ≥75 years receive NO bolus and a reduced maintenance dose (0.75 mg/kg vs 1 mg/kg)
Inappropriate dose capping: Do not arbitrarily cap doses at 100 mg in obese patients for ACS treatment (this differs from VTE prophylaxis)
Missing renal impairment: The CrCl <30 mL/min threshold requires once-daily dosing regardless of clinical scenario
Timing errors at PCI: Giving additional enoxaparin when the last dose was <8 hours ago increases bleeding risk unnecessarily
Using fondaparinux for PCI support: This is explicitly contraindicated due to catheter thrombosis risk 1
Monitoring Recommendations
Anti-Xa monitoring is generally not required for standard ACS patients with normal renal function and weight <150 kg. Consider monitoring in:
- Severe renal impairment (CrCl 15-30 mL/min)
- Extreme obesity (>150 kg)
- Recurrent ischemic events on therapy
- Unexplained bleeding
Target therapeutic anti-Xa levels: 0.5-1.0 IU/mL at 4 hours post-dose.